Clinical Trials
3 trialsNCT05482074 2024-01-19
Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2
Dana-Farber Cancer Institute
Phase 2 Withdrawn
NCT04184518 2020-06-02
CEDUVEAL-M
Grupo Español Multidisciplinar de Melanoma
Phase 2 Withdrawn
NCT01328106 2017-12-12
Efficacy and Safety Study of GSK1120212, a MEK Inhibitor, in Subjects With Uveal Melanoma
GlaxoSmithKline
Phase 2 Withdrawn